The power of negative metabolic imaging: negative FDG-PET/CT predicts infective endocarditis resolution
European Heart Journal - Cardiovascular Imaging · 2023
DOI: 10.1093/ehjci/jead175 ↗Kurz gefasst
Editorial in der Zeitschrift European Heart Journal - Cardiovascular Imaging, 2023. Verfasst von Patrizio Lancellotti und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Heart Valve Clinic, GIGA Cardiovascular Sciences, University of Liège Hospital, CHU Sart Tilman, Domaine Universitaire du S…. Hauptthemen laut MEDLINE: Endocarditis, Bacterial, Endocarditis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
This editorial refers to ‘Absence of infective endocarditis relapse when end-of-treatment fluorodeoxyglucose positron emission tomography/computed tomography is negative’, by C. Régis et al. doi:10.1093/ehjci/jead138. Infective endocarditis (IE) is a systemic disease with a myriad of possible complications. The initial presentation can be elusive, and the prognosis is varied, depending on the organ involved, the microorganisms, and patient factors. Multi-modality imaging techniques play complementary roles in the workup of patients with IE, especially in those with diagnostic uncertainties, e.g. possible or rejected IE by Duke criteria, but of high clinical suspicion, or those with intra-cardiac devices or prostheses. A metabolic imaging technique, fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), enables early identification of infection due to its ability to detect subclinical inflammatory activity before structural changes manifest. While the whole-body tomographic imaging aspect enables assessment of extra-cardiac complications, which can often be clinically silent.1,2 The 2015 ESC Modified Diagnostic Criteria included abnormal FDG-PET/CT uptake as either a major (around prosthetic valve) or a minor (silent emboli or infectious aneurysms) criterion.3 While the 2020 ACC/AHA Valvular Heart Disease Guideline gave a Class 2a recommendation for FDG-PET/CT as adjunct diagnostic imaging in patients with ‘possible IE’ by Modified Duke Criteria.4 FDG-PET/CT increased the sensitivity of Modified Duke Criteria, especially in patients with suspected prosthetic valve endocarditis (PVE) or cardiac implantable electronic devices. In native valve endocarditis (NVE), however, FDG-PET/CT has lower sensitivity as vegetation can often be small, below the spatial resolution of PET/CT.1
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Heart Valve Clinic, GIGA Cardiovascular Sciences, University of Liège Hospital, CHU Sart Tilman, Domaine Universitaire du Sart Tilman, B.35, Liège 4000, Belgium.
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore.
ORCID-Profile: Patrizio Lancellotti
Zitieren
APA
Lancellotti, P., & Go, Y. Y. (2023). The power of negative metabolic imaging: negative FDG-PET/CT predicts infective endocarditis resolution. European Heart Journal - Cardiovascular Imaging. https://doi.org/10.1093/ehjci/jead175
Vancouver
Lancellotti P, Go YY. The power of negative metabolic imaging: negative FDG-PET/CT predicts infective endocarditis resolution. European Heart Journal - Cardiovascular Imaging. 2023. doi:10.1093/ehjci/jead175
BibTeX
@article{Lancellotti2023,
author = {Lancellotti, Patrizio and Go, Yun Yun},
title = {The power of negative metabolic imaging: negative FDG-PET/CT predicts infective endocarditis resolution},
journal = {European Heart Journal - Cardiovascular Imaging},
year = {2023},
doi = {10.1093/ehjci/jead175}
}
EUVIMED